To the Editor,
We read with great interest the case report of central nervous system (CNS) involvement in primary adrenal lymphoma (PAL) in an elderly, HIV-seronegative male patient by Aydın et al. in the December issue of your journal [1] . In spite of initial partial regression of the CNS lesion, the patient succumbed to progressive CNS disease after rituximabbased chemotherapy and whole-brain radiotherapy. Though the pathogenesis and therapeutic aspects of this lymphoma at both anatomic sites were highlighted, there was a lack of precise information regarding adrenal function (prior autoimmune adrenalitis) and detailed immunophenotype of PAL (germinal center or non-germinal center), which could have also influenced the clinical outcome in this patient.
PAL is an enigmatic entity with nearly 200 cases reported in the world literature up to 2013 [2, 3] . Out of all parameters studied, adrenal insufficiency, high lactate dehydrogenase (LDH), B symptoms, and initiation of chemotherapy have been reported to be the significant independent predictors of poor prognosis in PAL. Secondary CNS involvement is known to occur in 2%-10% cases of diffuse large B-cell lymphoma (DLBCL) and confers a poor prognosis [3] . Of all reported cases of PAL (1980-2013, including the case by Aydın et al.), 18 patients had CNS involvement [7 (39%) at presentation, 11 (61%) at relapse (within 6 months of diagnosis)]. Their mean age was 63.8 years (range: 42 to 82 years), 17/18 (94.5%) were male, 16/16 (100%) had bilateral PAL, 10/13 (77%) had a mean lesion size of 5 cm or more, 3/18 (16.6%) had disseminated disease at presentation, 1/18 (5.5%) had coexistent secondary involvement of thyroid, 9/11 (82%) had adrenal insufficiency, 11/13 (84.6%) had elevated LDH, and 11/14 (78.5%) had B symptoms. Thirteen of 18 (72%) had DLBCL, 2 had peripheral T-cell lymphoma, 1 had Burkitt-like lymphoma, and the remaining 2 (11%) had non-Hodgkin lymphoma unclassified [2, 3] (Table 1) . Though patients with PAL are at risk of CNS involvement, there has been no consensus, at present, regarding CNSdirected prophylaxis in these patients. As most of the reported CNS events in PAL cases occurred prior to the rituximab era, larger in-depth prospective studies in the post-rituximab era will, hopefully, throw more light on this topic in future. Turk 
